Michael Kolodziej, MD, explains, the benefit of using biomarkers from a payer perspective to ensure that the right patient gets the right treatment.
Michael Kolodziej, MD, explains, the benefit of using biomarkers from a payer perspective to ensure that the right patient gets the right treatment.
“Many of the new therapies, whether they be targeted agents or immunotherapies are extremely expensive,” he said. “We can get into long debate about what the right or fair price is, but I think because of the high cost, there is a lot of scrutiny in the managed care world to make sure that the right patient gets the treatment.”
He added that it can be difficult to know where treatments belong in the sequence of therapy. While some people are of the opinion that these treatments should be used earlier rather than later, payers prefer to manage to what the FDA decides.
Lymphoma Research Foundation CEO on Biden’s Cancer Moonshot, Financial Toxicity
February 3rd 2022On this episode of Managed Care Cast, we speak with Meghan Gutierrez, CEO of the Lymphoma Research Foundation, about financial toxicity, how the pandemic has affected patients’ financial needs when they have cancer, health care disparities and care gaps, and more.
Listen
Panel Addresses How Payers, Providers Can Optimally Use Real-World Evidence to Advance Cancer Care
November 10th 2022Utilizing real-world evidence that applies to the specific care needs of certain patient populations can promote timely decision-making among payers and providers on the use of effective cancer therapies available on the market, said panelists at the 2022 Patient-Centered Oncology Care® (PCOC) meeting.
Read More
2 Clarke Drive
Cranbury, NJ 08512